Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for major depressive disorder and related depressive conditions in adult patients. GNH USA supplies Mirtazapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the antidepressant drug class to address mood disorders. - Major depressive disorder: improves mood, sleep and overall functional capacity. - Depression with anxiety: reduces both depressive and anxiety symptoms. - Depression with insomnia: helps restore sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Severe hypersensitivity reactions - Hepatic dysfunction - Unexplained bleeding or bruising

Before initiating therapy, consider the following safety measures. - Hepatic function assessment: adjust use in patients with liver impairment. - Monitor mood: watch for worsening depression or emergent suicidal ideation. - Cardiovascular caution: use carefully in patients with existing heart disease. - Elderly patients: start at lower doses due to increased sedation risk. - Discontinuation: avoid abrupt stopping to reduce withdrawal phenomena. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce therapeutic effect. - Antihypertensive drugs: potential additive blood‑pressure lowering effect. - Lithium: monitor lithium levels for possible toxicity. - NSAIDs or anticoagulants: increased risk of gastrointestinal bleeding.